KalVista begins trial for sebetralstat in children with hereditary angioedema

KalVista Pharmaceuticals initiated the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema, or HAE. The trial will enroll approximately 24 children aged 2 to 11 years across seven countries. If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 – 11 years, and only the second FDA-approved on-demand therapy of any type in this population.